Day: April 25, 2022

Hazy Oasis Pale Ale and Featherhammer Ale Available This Week Watertown, NY, April 25, 2022 (GLOBE NEWSWIRE) — 1812 BREWING COMPANY, INC. (OTC Pink: KEGS) (the “Company”) is pleased to announce that on the heels of its flagship War of 1812 Amber Ale earning a top medal in the 2022 New York International Beer Competition, it is releasing two new beers this week.  Available at its Sackets Harbor location will be the new Hazy Oasis Pale Ale and Featherhammer Ale. Hazy Oasis Pale Ale (4.7% ABV) is an American-style hazy pale ale brewed with a variety of hops including Mosaic and Citra and fermented with a special yeast that elevates these hops’ flavors.  When drinking Hazy Oasis you’ll notice tropical aromas of mango, guava, and passion fruit that make it easy to drink.  Featherhammer Ale (8% ABV) is a German style Maibock...

SteelPhalt has introduced the world’s first carbon-negative steel slag aggregate-based asphalt using lignin binder product made from trees. CAMP HILL, Pa., April 25, 2022 (GLOBE NEWSWIRE) — Harsco Corporation (NYSE: HSC), a global market leader providing environmental solutions, announced SteelPhalt, a part of its Harsco Environmental division has launched a carbon-negative asphalt product. SteelPhalt’s asphalt products use 95% recycled steel slag. Prior SteelPhalt asphalt products use bitumen to bind the asphalt. Bitumen is an oil-based binder product with a significant carbon footprint. SteelPhalt’s new asphalt product, called SteelSurf ECO+, uses kraft lignin-based Lineo®, a renewable bio-based substance, supplied by GautamZenUK in collaboration with Stora Enso, as an alternative to bitumen dramatically reducing the product’s...

Results from patient preference questionnaire indicate that people with narcolepsy preferred the once-nightly over the twice-nightly dosing regimen for oxybates Nocturnal adverse event questionnaires characterize the burden associated with the second dose required for twice-nightly oxybatesDUBLIN, Ireland, April 25, 2022 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the presentation of interim data from the ongoing RESTORE open-label extension/switch study of FT218 at the 2022 American Academy of Neurology Annual (AAN) Meeting being held virtually from April 24-26, 2022. FT218 is the Company’s lead drug candidate, an investigational formulation of sodium oxybate designed to be taken once at bedtime for the treatment...

Conference call and webcast to follow at 5:30 p.m. EDT LONG BEACH, NY , April 25, 2022 (GLOBE NEWSWIRE) — authID.ai (Nasdaq: AUID), a leading provider of secure, mobile, biometric identity authentication solutions, today announced it will report financial results for the first quarter ended March 31, 2022 on Monday, May 9, after market close. Following the earnings release, authID.ai Chief Executive Officer Tom Thimot, and Chief Financial Officer Stu Stoller will host a webcast and conference call at 5.30 p.m. EDT to discuss the financial results and provide a corporate update. To listen to the webcast and view the presentation, investors can follow this link: https://edge.media-server.com/mmc/p/3sjqwpia. The slides can also be accessed via authID.ai’s Investor Relations web page at: https://investors.authid.ai/  To participate...

Interim analysis provides response data from 7 evaluable patients including two additional patients, one with non-Hodgkin lymphoma (NHL) and one with acute lymphoblastic leukemia (ALL) Six-month CR rate of 29%, including 1 ongoing CR at 34 weeks in heavily pretreated patients Encouraging response rates at low doses: 57% overall response rate (ORR), 71% disease control rate (DCR) Two responses observed in patients who failed previous autologous CAR-T therapy Allogeneic CD19 CAR-NKT cells well tolerated with 3 cases of grade 1 cytokine release syndrome (CRS), no immune effector cell-associated neurotoxicity syndrome (ICANS) and no graft versus host disease (GvHD) Early responses at low doses suggest promise of “off-the-shelf” cancer immunotherapy platformBUFFALO, N.Y., April 25, 2022 (GLOBE NEWSWIRE) — Athenex, Inc., (NASDAQ:...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced publication of a preclinical report on petosemtamab (Peto, MCLA-158: LGR5 x EGFR Biclonics®) in the journal Nature Cancer. The publication will be available at 11:00 a.m. ET today. The report describes the use of the company’s Biclonics® platform to perform a large-scale functional screen of bispecific antibodies resulting in selection of Peto, a bispecific antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G protein-coupled receptor (LGR5). Peto displayed potent growth inhibition of colorectal...

MUMBAI, India and JOHNS CREEK, Ga, April 25, 2022 (GLOBE NEWSWIRE) — At the Times Network’s India Economic Conclave in Mumbai on April 22nd 2022, Ebix Chairman Robin Raina said the dream of a self-reliant India cannot be realized without advancing into intellectual property creation as a top national priority. The full video of the 30-minute fireside chat at the India Economic Conclave, with Times Network Executive Editor Mihir Bhatt can be seen on – https://ebixcash.com/allnews/#videos Times Network’s flagship annual event – India Economic Conclave (IEC), was held on Thursday and Friday last week in Mumbai, India at the National Centre for the Performing Arts (NCPA). The two-day event featured many insightful sessions with luminaries such as Former US Secretary of State Mrs. Hilary Clinton, UK Prime Minister Boris Johnson...

RESEARCH TRIANGLE PARK, N.C., April 25, 2022 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it will report first quarter 2022 financial results before the market opens on Monday, May 9, 2022. Company management will host a corresponding conference call at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (844) 467-7754 for domestic callers or (270) 215-9366 for international callers, followed by Conference ID: 1388417. A live and archived webcast of the event will be available on the Investor Relations section of the Science 37 website at https://investors.science37.com/. About Science 37 Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to enable universal access to clinical...

To Nasdaq Copenhagen A/S         New fixed-rate bonds Nykredit opens the following new fixed-rate bonds.3.5% 30-years annuity SDO with interest-only option up to 10 years 3% 20-years annuity SDO 2% 10-years annuity SDOThe new bonds will be used to fund lending in Totalkredit A/S and Nykredit Realkredit A/S. The Final Bond Terms will be published in separate stock exchange announcement. Questions may be addressed to Christian Mauritzen, tel +45 44 55 10 14, or Lars Mossing Madsen, tel +45 44 55 11 66.AttachmentForhåndsmeddelse – UK – 30-årige